In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5

The replacement of the Omicron BA.1 variant of SARS-CoV-2 by the BA.2 and the rapid growth of the BA.5 sub lineage, which have both different sets of mutations in the spike glycoprotein, alters the spectrum of activity of therapeutic antibodies currently licensed in the European Union. Using clinica...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2022-07, Vol.12 (1), p.12609-6, Article 12609
Main Authors: Touret, Franck, Baronti, Cécile, Pastorino, Boris, Villarroel, Paola Mariela Saba, Ninove, Laetitia, Nougairède, Antoine, de Lamballerie, Xavier
Format: Article
Language:English
Subjects:
631/326
631/326/596
Antibodies
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neutralizing
Antibodies, Viral
COVID-19 Drug Treatment
Drug Combinations
Humanities and Social Sciences
Humans
Life Sciences
Monoclonal antibodies
multidisciplinary
SARS-CoV-2 - genetics
Science
Science (multidisciplinary)
Severe acute respiratory syndrome coronavirus 2
Spike glycoprotein
Spike Glycoprotein, Coronavirus - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The replacement of the Omicron BA.1 variant of SARS-CoV-2 by the BA.2 and the rapid growth of the BA.5 sub lineage, which have both different sets of mutations in the spike glycoprotein, alters the spectrum of activity of therapeutic antibodies currently licensed in the European Union. Using clinical strains of the Omicron BA.2 and BA.5 variants, we compared the neutralising power of monoclonal antibodies against the Omicron BA.1, BA.2 and BA.5 variants, using an ancestral strain (lineage B.1, D614G) and a Delta variant strain as reference. Sotrovimab/Vir-7831 is less active against BA.2 than against BA.1 (fold change reduction ~ 1,4) and even less active against BA.5 (fold change reduction ~ 2.7). Within the Evusheld /AZD7442 cocktail, Cilgavimab/AZD1061 is more active against BA.2 and BA.5 than against BA.1 (fold change increase ~ 32), whilst the very low activity of Tixagevimab/AZD8895 against BA.1 is not enhanced against BA.2 nor BA.5. In total, compared to BA.1, the activity of the Evusheld/AZD7442 is significantly improved against BA.2 while BA.5 is intermediate but closer to BA.2.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-16964-z